Staff Profile Pages

LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib

Authors: Hickish, T., Mehta, A., Jain, M., Huang, C.-S., Kovalenko, N., Udovitsa, D., Pemberton, K., Uttenreuther-Fischer, M. and Tseng, L.-M.

Journal: CANCER RESEARCH

Volume: 72

eISSN: 1538-7445

ISSN: 0008-5472

DOI: 10.1158/0008-5472.SABCS12-OT1-1-17

Source: Web of Science (Lite)